Phase 4 N=61 Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
Posttransplant Diabetes Mellitus
Primary: 2-hour Oral Glucose Tolerance Test-derived Blood Sugar — 141.00; 165.22 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=36 A Clinical Trial to Prevent New Onset Diabetes After Transplantation
Prevention of New Onset Diabetes Among Kidney Transplant Patients
Primary: The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation — 3; 1 Participants — p=0.87
Phase 2 N=9 Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation
Pre Diabetes
Primary: Progression From Prediabetes to Diabetes — 0; 1 Participants
Phase 4 N=29 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Kidney Transplant · Diabetes Mellitus, Type 2 · Diabetic Nephropathy
Primary: Freedom From Insulin Therapy Post Transplant — 3; 4 Participants
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
N/A N=104 IV Insulin Protocol in Diabetes and Renal Transplantation
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
Phase 4 N=6 Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Nephrotoxicity
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2
Phase 2 N=7 Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
Diabetes Mellitus, Type I
Primary: Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point…
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Phase 2 N=527 Calcineurin Inhibitor Sparing After Kidney Transplantation
CNI Side Effects
Primary: Phase I: The Minimization of Negative Side Effects - Patient Survival — 99; 98 percentage of participants
Phase 3 N=90 Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
Osteoporosis · Chronic Kidney Disease
Primary: Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12 — 4.5; -0.3 percent change — p=<0.001
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Phase 3 N=49 Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans
End Stage Renal Disease · Kidney Transplantation
Primary: Cumulative One-year Acute Rejection Rates — 7 Participants — p=0.28
N/A N=40 Using mTOR Inhibitors in the Prevention of BK Nephropathy
BK Viremia · BK Nephropathy
Primary: Number of Participants With BK Viral Load <600 Copies/mL — 13; 17 Participants
Phase 2 N=7 Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
Diabetes Mellitus, Type 1
Primary: Insulin Independence. — 2 Participants
Phase 2 N=42 Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
Renal Transplant Osteodystrophy
Primary: Bone Mineral Density of Spine at 6 Months — 0.98; 0.97 gm/cm^2
Phase 2 N=290 Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Kidney Transplant
Primary: The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups. — 52.45; 57.35 mL/min/1.73m2 — p=0.099
Phase 2 N=37 Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Graft vs Host Disease · Hematopoietic Stem Cell Transplantation
Primary: Percentage of Patients With Grade II-IV Acute GvHD by Day +100 Following Transplant — 94.4 percentage of participants
Phase 4 N=180 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
End-stage Renal Disease
Primary: Chronic Allograft Nephropathy (Cumulative Calcineurin-inhibitor Nephrotoxicity/Transplant Nephropathy) Per Protocol Surveillance Kidney Biopsies (Banff Grading…
N/A N=42 Improving Adherence in Nonadherent Kidney Transplant Patients
Medication Adherence · Kidney Transplantation
Primary: Change in Number of Patients Being Adherent/Non-aherent After the Intervention — 15; 30; 34; 35 Participants
Phase 2 N=170 Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
Type 1 Diabetes
Primary: Event-Specific Survival Comparisons — 22; 8; 9; 1 Participants — p=0.01
Phase 4 N=30 Spironolactone After Liver Transplant
Transplant, Liver
Primary: Glomerular Filtration Rate (GFR) — 69; 64 ml/min/1.73m^2 — p=0.0001
Phase 4 N=122 Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
Hepatitis C · Transplantation Disease Transmission
Primary: Proportion of Participants With HCV RNA Level Below Limits of Quantification (LOQ) — 23 Participants
Phase 3 N=530 A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
Diabetic Nephropathies · Coronary Artery Disease
Primary: iGFR at the End of the Wash-out Period — 61.2; 61.2 ml/min/1.73 m^2 — p=0.999
Phase 3 N=32 Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
Transplant; Failure, Kidney
Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32
Phase 3 N=288 Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
Delayed Graft Function
Primary: Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplant — 35.9; 41.7; 33.8; 39.6 percentage of participants — p=0.3983
Phase 2 N=10 Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Kidney Transplantation · Kidney Disease
Primary: Number of Acute Rejections in All Enrolled Participants — 1 Rejection Events
N/A N=338 Vascular Risk After Kidney Transplantation
Cardiovascular Disease · Chronic Kidney Disease · Diabetes
Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)
Phase 2 N=61 Bone Mass and Strength After Kidney Transplantation
End Stage Renal Disease · Kidney Transplantation · Bone Loss
Primary: Percent Change in Bone Density From Pre to Post-calcitriol Treatment Compared to Placebo as Assessed by Both Standard Methodologies — -0.81; -0.70 percent change
N/A N=30 A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
Acute Graft Rejection · Diabetes
Primary: Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection — 2; 2 Participants